XML 129 R17.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Subscription Agreement | 12 Months Ended
--- | ---
Dec. 31, 2023
Subscription Agreement [Abstract] |
Subscription Agreement | Note 8 — Subscription Agreement On December 18, 2023, the Company entered into a subscription agreement (the “Subscription Agreement”) with the PMX Investor, who became a stockholder of Onconetix at the closing of the PMX Transaction (see Notes 5 and 11) for the sale of 20 million units, each comprised of 1 share of common stock and 0.30 pre-funded warrants (the “Units”) at $0.25 per Unit. The Subscription Agreement includes a make-whole provision which requires the issuance of additional shares of common stock in the event that the 270-day volume weighted average price (“270 VWAP”) after the closing of the Subscription Agreement, is below $0.25. The Subscription Agreement will only close upon obtaining Stockholder Approval for certain transactions involving the Company’s Series B Preferred Stock, as further described in Note 5. The Subscription Agreement is accounted for as a liability in accordance with ASC 480, as the make-whole provision could result in a variable number of shares being issued upon settlement. The subscription agreement liability is measured at fair value at the commitment date and at each subsequent reporting period, with changes in fair value recorded as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company recorded the fair value of the Subscription Agreement liability at the issuance date of approximately $0.8 million, as an acquisition related cost, as the Subscription Agreement was a condition to close the PMX Transaction (see Note 5). As of December 31, 2023, the fair value of the subscription agreement liability is estimated to be approximately $0.9 million, determined using a Monte-Carlo option pricing model, and the Company estimated a 55.0% probability that the Subscription Agreement will close. The significant assumptions used in the Monte-Carlo model, which utilizes Level 3 inputs (see Note 3), are as follows as of the commitment date and at December 31, 2023:
|  | December 18, 2023 |  | December 31, 2023
Exercise price |  | $ | 0.25 |  |  | $ | 0.25 |
Term (years) |  |  | 1.5 |  |  |  | 1.2 |
Expected stock price volatility |  |  | 100 | % |  |  | 95 | %
Risk-free rate of interest |  |  | 4.64 | % |  |  | 4.64 | %

X
- References No definition available. + Details
Name: | onco_SubscriptionAgreementDisclosureAbstract
Namespace Prefix: | onco_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for subscription agreement. + References No definition available. + Details
Name: | onco_SubscriptionAgreementDisclosureTextBlock
Namespace Prefix: | onco_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration